Halotestin (Fluoxymesterone)
FDA ApprovedOral Anabolic Steroid | Extreme Strength & Aggression
Community Research
Join others researching Halotestin — share findings, ask questions, and learn from real experiences
Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use.
Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue. The compound's performance-enhancing effects are largely mediated through the central nervous system, increasing aggression, motivation, and perceived energy through androgen receptor activation in the brain. Fluoxymesterone also stimulates erythropoietin production, increasing red blood cell mass and oxygen-carrying capacity, which was the basis for its historical use in treating certain anemias. It enhances hemoglobin synthesis and may improve muscular endurance through improved oxygen delivery. The 17-alpha-methylation allows oral bioavailability but imposes significant hepatic stress, as the liver must process the intact steroid through first-pass metabolism. Fluoxymesterone suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, and its extreme androgenic load can rapidly affect mood, lipid profiles, and prostate tissue.
Molecular Data
Research Indications
Originally FDA-approved for testosterone replacement in hypogonadal men. Fluoxymesterone was used to treat delayed puberty and androgen deficiency, though it has been almost entirely replaced by injectable testosterone and transdermal preparations due to its hepatotoxicity and unfavorable side effect profile.
FDA-approved for palliative treatment of androgen-responsive, advanced inoperable breast cancer in women, typically 1-5 years post-menopause. This indication is rarely used today due to the availability of aromatase inhibitors and targeted therapies with superior safety profiles.
Used by powerlifters and strength athletes in the final 2-4 weeks before a competition to maximize strength output, aggression, and neural drive without adding bodyweight or water retention. The compound's effects on the central nervous system produce a pronounced increase in competitive intensity.
Employed by competitive bodybuilders in the last 2-4 weeks before stage to enhance muscle hardness, vascularity, and visual density without water retention. The non-aromatizing nature ensures no subcutaneous water accumulation during the critical final phase of contest preparation.
Historically used by fighters and combat sport athletes to increase aggression and power output while staying within a weight class, as it adds no water weight. This use carries significant ethical and regulatory concerns given anti-doping testing.
Dosing Protocols
Fluoxymesterone is exclusively administered orally as a 17-alpha-alkylated steroid. Pharmaceutical tablets have been produced in 2 mg, 5 mg, and 10 mg doses. The 17-alpha-methylation provides oral bioavailability but makes halotestin one of the most hepatotoxic oral anabolic steroids available. Due to its extreme liver toxicity, cycles must be kept very short and liver support supplementation is considered essential.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical - Hypogonadism (Historical) | 5-20 mg/day | Divided into 2-4 doses daily | Oral |
| Performance - Strength Peaking | 10-20 mg/day | Split into 2 doses (morning and 1-2 hours pre-training) | Oral |
| Performance - Pre-Contest Hardening | 10-20 mg/day | Split into 2 doses daily | Oral |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)
- Pronounced aggression and irritability
- HDL cholesterol suppression and LDL elevation
- Elevated blood pressure
- Headaches (frequently reported, may be related to blood pressure changes)
- Suppression of endogenous testosterone production
- Oily skin and acne
- Decreased appetite (potentially related to liver stress)
Stop Signs - Discontinue if:
- Yellowing of skin or eyes (jaundice, indicating serious liver damage)
- Severe or persistent right upper quadrant abdominal pain
- Dark-colored urine or pale/clay-colored stools
- Extreme or uncontrollable aggression that affects daily functioning or relationships
- Persistent severe headaches unresponsive to standard treatment
- Chest pain, difficulty breathing, or signs of cardiovascular distress
- Unusual bleeding or bruising
- Nausea, vomiting, or profound fatigue suggesting hepatic compromise
Contraindications
- Known or suspected prostate cancer
- Breast cancer in males
- Pregnancy (Category X - causes fetal harm)
- Active liver disease or existing hepatic impairment
- Severe cardiovascular disease or uncontrolled hypertension
- Hypercalcemia
- Nephrosis or nephrotic phase of nephritis
- History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use
- Hypersensitivity to fluoxymesterone or any formulation component
Quality Checklist
Good Signs
- Pharmaceutical-grade product with manufacturer lot number and expiration date (Halotestin brand or authorized generic)
- Proper labeling with correct dosage per tablet, lot number, and expiration date
- Tablets are uniform in size, color, and shape with consistent imprinting
- Prescribed by a licensed physician with documented clinical indication
- Third-party lab testing confirming identity, potency, and absence of contaminants
Warning Signs
- Underground lab (UGL) product without pharmaceutical-grade verification
- Tablets with inconsistent sizing, crumbling, or no manufacturer imprint
- No third-party certificate of analysis available
- Product labeled at unusually high doses per tablet (above 20 mg)
- Packaging that appears unprofessional or has spelling errors
Bad Signs
- Product with no labeling or verifiable source information
- Lab testing reveals substituted compound (methyltestosterone or other cheaper steroid sold as halotestin)
- Contaminated product with heavy metals, bacteria, or undisclosed active ingredients
- Expired product or product stored improperly
- Severe or unexpected side effects suggesting mislabeled or adulterated product
References
- Fluoxymesterone: A Review of Its Pharmacology and Therapeutic UseLlewellyn, W.Anabolics (Reference Guide) (2011)
Comprehensive pharmacological profile of fluoxymesterone detailing its extreme androgenic potency (1900 androgenic rating), non-aromatizing nature, and clinical applications in hypogonadism and breast cancer, alongside documentation of its significant hepatotoxicity relative to other oral anabolic steroids.
- Hepatotoxicity of Anabolic Androgenic SteroidsBond, P., Llewellyn, W., Van Mol, P.Current Opinion in Endocrinology, Diabetes and Obesity (2016)
Review documenting the spectrum of hepatotoxicity associated with 17-alpha-alkylated anabolic steroids including fluoxymesterone, ranging from transient enzyme elevations to cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma, with fluoxymesterone identified as one of the most hepatotoxic compounds in this class.
- Androgens and ErythropoiesisShahidi, N.T.New England Journal of Medicine (1973)
Landmark paper establishing the role of androgens including fluoxymesterone in stimulating erythropoietin production and red blood cell synthesis, which formed the basis for the historical use of halotestin in treating aplastic anemia and other refractory anemias before the availability of recombinant erythropoietin.
- A Comparison of the Effects of Fluoxymesterone and Testosterone Propionate on the Nitrogen Balance of Patients with Breast CancerGordan, G.S., Eisenberg, E., Loken, H.F., Gardner, B., Halden, A.Journal of Clinical Endocrinology & Metabolism (1956)
Early clinical study comparing fluoxymesterone to testosterone propionate in breast cancer patients, demonstrating that oral fluoxymesterone achieved comparable nitrogen retention and anti-tumor activity to injectable testosterone, establishing its clinical viability as an oral androgen therapy.
- Adverse Effects of Anabolic-Androgenic Steroids: A Literature ReviewHoffman, J.R., Ratamess, N.A.Journal of Sports Medicine and Physical Fitness (2006)
Comprehensive review of adverse effects associated with anabolic-androgenic steroid use including cardiovascular, hepatic, endocrine, and psychological effects, with specific discussion of the elevated hepatotoxic risk associated with 17-alpha-alkylated compounds such as fluoxymesterone.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.